Eagle Health Investments LP acquired a new position in Illumina, Inc. (NASDAQ:ILMN – Free Report) in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 187,413 shares of the life sciences company’s stock, valued at approximately $32,953,000. Illumina accounts for approximately 5.5% of Eagle Health Investments LP’s investment portfolio, making the stock its 6th biggest position. Eagle Health Investments LP owned approximately 0.12% of Illumina as of its most recent SEC filing.
Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Empowered Funds LLC grew its position in shares of Illumina by 113.7% during the 1st quarter. Empowered Funds LLC now owns 9,284 shares of the life sciences company’s stock worth $737,000 after buying an additional 4,940 shares during the period. Sivia Capital Partners LLC bought a new position in Illumina in the second quarter valued at approximately $621,000. CW Advisors LLC acquired a new stake in Illumina during the 2nd quarter worth $275,000. Marshall Wace LLP raised its position in shares of Illumina by 49.0% during the 2nd quarter. Marshall Wace LLP now owns 59,645 shares of the life sciences company’s stock valued at $5,691,000 after acquiring an additional 19,618 shares during the last quarter. Finally, Cresset Asset Management LLC raised its position in shares of Illumina by 30.9% during the 2nd quarter. Cresset Asset Management LLC now owns 7,404 shares of the life sciences company’s stock valued at $706,000 after acquiring an additional 1,748 shares during the last quarter. 89.42% of the stock is owned by institutional investors.
Illumina Price Performance
Shares of ILMN opened at $205.00 on Thursday. The stock has a 50 day simple moving average of $185.90 and a 200 day simple moving average of $151.49. Illumina, Inc. has a 52-week low of $88.00 and a 52-week high of $207.00. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.40 and a current ratio of 1.80. The firm has a market capitalization of $30.95 billion, a PE ratio of 38.25, a P/E/G ratio of 2.65 and a beta of 1.45.
Wall Street Analysts Forecast Growth
Several research firms have recently issued reports on ILMN. Barclays raised their price target on Illumina from $145.00 to $160.00 and gave the stock an “underweight” rating in a research report on Friday, July 31st. Sanford C. Bernstein reiterated a “market perform” rating and issued a $215.00 price objective on shares of Illumina in a report on Friday, July 31st. Wall Street Zen raised Illumina from a “hold” rating to a “buy” rating in a research note on Saturday, August 1st. TD Cowen raised their target price on Illumina from $192.00 to $210.00 and gave the stock a “hold” rating in a report on Friday, July 31st. Finally, Daiwa Securities Group upgraded Illumina from a “neutral” rating to an “outperform” rating and set a $155.00 target price for the company in a research report on Thursday, May 14th. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, six have assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $188.40.
Check Out Our Latest Report on ILMN
Insider Activity at Illumina
In other news, Director Keith A. Meister sold 457,858 shares of the business’s stock in a transaction dated Tuesday, August 4th. The stock was sold at an average price of $200.10, for a total value of $91,617,385.80. Following the sale, the director directly owned 2,372,694 shares in the company, valued at $474,776,069.40. The trade was a 16.18% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CAO Scott D. Ericksen sold 1,500 shares of the business’s stock in a transaction that occurred on Thursday, May 28th. The shares were sold at an average price of $150.10, for a total value of $225,150.00. Following the completion of the sale, the chief accounting officer owned 14,946 shares in the company, valued at $2,243,394.60. The trade was a 9.12% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 1,415,351 shares of company stock valued at $255,966,311 in the last quarter. 2.90% of the stock is currently owned by company insiders.
Illumina Profile
Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.
The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.
Featured Stories
- Five stocks we like better than Illumina
- Bloom Energy’s AI Surge Meets a Valuation Reality Check
- Target Is Winning Shoppers Back—Can the Rally Reach $180?
- IonQ’s Space Contract Points to a New Frontier for Quantum Investors
- Is Apple’s AI Strategy Smarter Than Skeptics Think?
Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN – Free Report).
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.
